HPV-16/18 L1/AS04

BIOLOGICAL3 trials

Sponsors

GlaxoSmithKline

Conditions

Infections, Papillomavirus

Phase 3

Human Papilloma Virus Vaccine Consistency and Non-inferiority Trial in Young Adult Women With GSK Bio HPV-16/18

CompletedNCT00169494

GlaxoSmithKlineInfections, Papillomavirus

Start: 2004-09-30End: 2005-07-31Updated: 2016-09-12

Human Papilloma Virus Vaccine Safety and Immunogenicity Trial in Young Adolescent Women With GSK Bio HPV-16/18.

CompletedNCT00196924

GlaxoSmithKlineInfections, Papillomavirus

Start: 2004-06-30End: 2006-03-31Updated: 2017-03-23

Evaluate the Immunogenicity & Safety of GSK Biologicals' HPV Vaccine in Female Subjects Aged 10-14 Years

CompletedNCT00290277

GlaxoSmithKlineInfections, Papillomavirus

Start: 2005-11-30End: 2006-08-31Updated: 2016-09-28

Related Papers

Head-to-head comparison of two human papillomavirus vaccines for efficacy against cervical intraepithelial neoplasia grade 3 and adenocarcinoma in situ—population-based follow-up of two cluster-randomized trials

Frontiers in Cellular and Infection Microbiology2024-09-093 citations

Human papillomavirus vaccine efficacy against invasive, HPV-positive cancers: population-based follow-up of a cluster-randomised trial

BMJ Open2021-12-0143 citations

A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years

Human Vaccines & Immunotherapeutics2019-07-0357 citations

Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point—registry-based follow-up of <i>three cohorts from randomized trials</i>

BMJ Open2017-08-0188 citations

Long-term immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in 10- to 14-year-old girls: open 6-year follow-up of an initial observer-blinded, randomized trial.

2014-12-0117 citations

Results disclosure of papilloma vaccine studies in humans completed before January 1st, 2011.

Figshare2014-01-01

Results disclosure of papilloma vaccine studies in humans co.

Figshare2014-01-01

Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14 years.

2012-02-0144 citations